Pediatric Endocrine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Endo-ERN Center for Rare Endocrine Conditions, 40138 Bologna, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, 16147 Genoa, Italy.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1020-e1031. doi: 10.1210/clinem/dgab784.
Nationwide data on children diagnosed with craniopharyngioma (CP) are not available in Italy.
This work aimed to identify patients' characteristics, type of surgical approach, complications and recurrences, number of pituitary deficits, and number of patients starting growth hormone (GH) treatment.
A retrospective multicenter collection took place of 145 patients aged 0 to 18 years who underwent surgery for CP between 2000 and 2018, and followed up in 17 Italian centers of pediatric endocrinology.
Age at diagnosis was 8.4 ± 4.1 years. Duration of symptoms was 10.8 ± 12.5 months and headache was most frequent (54%), followed by impaired growth (48%) and visual disturbances (44%). Most lesions were suprasellar (85%), and histology was adamantinomatous in all cases but two. Surgical approach was transcranial (TC) in 67.5% of cases and transsphenoidal (TS) in 31.%. The TC approach was prevalent in all age groups. Postsurgery complications occurred in 53% of cases, with water-electrolyte disturbances most frequent. Radiotherapy was used in 39% of cases. All patients but one presented with at least one hormone pituitary deficiency, with thyrotropin deficiency most frequent (98.3%), followed by adrenocorticotropin (96.8%), arginine vasopressin (91.1%), and GH (77.4%). Body mass index (BMI) significantly increased over time. A hypothalamic disturbance was present in 55% of cases. GH therapy was started during follow-up in 112 patients at a mean age of 10.6 years, and 54 developed a recurrence or regrowth of the residual lesion.
CP is often diagnosed late in Italy, with TC more frequent than the TS surgical approach. Postsurgery complications were not rare, and hypopituitarism developed almost in all cases. BMI shows a tendency to increase overtime.
意大利尚无关于儿童颅咽管瘤(CP)诊断的全国性数据。
本研究旨在明确患者的特征、手术入路类型、并发症和复发、垂体功能减退的数量以及开始生长激素(GH)治疗的患者数量。
回顾性多中心收集了 2000 年至 2018 年间在意大利 17 个儿科内分泌中心接受手术治疗的 145 名 0 至 18 岁的 CP 患者的数据。
诊断时的年龄为 8.4±4.1 岁。症状持续时间为 10.8±12.5 个月,最常见的症状是头痛(54%),其次是生长受损(48%)和视力障碍(44%)。大多数病变位于鞍上(85%),除了两例外,所有病例的组织学均为造釉细胞瘤型。67.5%的病例采用经颅(TC)入路,31.0%的病例采用经蝶窦(TS)入路。TC 入路在所有年龄段均更为常见。术后并发症发生率为 53%,最常见的是水-电解质紊乱。39%的病例使用了放疗。除了 1 例患者外,所有患者均至少存在一种垂体激素缺乏,促甲状腺激素缺乏最常见(98.3%),其次是促肾上腺皮质激素(96.8%)、精氨酸血管加压素(91.1%)和 GH(77.4%)。BMI 随时间显著增加。55%的病例存在下丘脑功能障碍。在随访期间,112 例患者平均年龄为 10.6 岁开始接受 GH 治疗,54 例患者出现残余病变的复发或再生长。
意大利 CP 常常诊断较晚,TC 入路比 TS 入路更常见。术后并发症并不罕见,几乎所有病例均发生垂体功能减退。BMI 随时间有增加的趋势。